Are losartan, amlodipine (Norvasc), and hydrochlorothiazide (HCTZ) contraindicated in breastfeeding mothers?

Safety of Losartan, Amlodipine (Norvasc), and Hydrochlorothiazide During Breastfeeding

Losartan should be avoided during breastfeeding due to limited safety data, while amlodipine (Norvasc) and hydrochlorothiazide are considered safe with specific precautions. 1

Individual Drug Recommendations

Losartan (ARB) - AVOID

• Losartan has limited safety data and should be avoided during breastfeeding. 1
• The 2025 Circulation guidelines classify losartan as having "limited safety data" for lactation. 1
• The European Society of Cardiology guidelines recommend that angiotensin II receptor blockers (ARBs) should be avoided during breastfeeding. 1
• Transfer to breast milk is unknown, and there is insufficient evidence to determine infant safety. 1

Amlodipine (Norvasc) - SAFE

• Amlodipine is safe during breastfeeding with a relative infant dose (RID) of 1.7-4.3%. 1
• The FDA drug label states that amlodipine is present in human milk at an estimated median relative infant dose of 4.2%, with no adverse effects observed in breastfed infants. 2
• RID levels below 10% are considered safe for breastfeeding. 1
• The 2025 Circulation guidelines list amlodipine as a safe alternative agent for postpartum hypertension management. 1
• A 2002 systematic review found that calcium channel blockers with low milk-to-plasma ratios, including amlodipine, appear safe for nursing mothers. 3

Hydrochlorothiazide (HCTZ) - SAFE WITH CAUTION

• Hydrochlorothiazide is safe during breastfeeding with RID of 0.6-1.2%, but doses above 25 mg/day may decrease breast milk production. 1
• The 2025 Circulation guidelines classify HCTZ as safe but note the potential for reduced lactation at higher doses. 1
• Maximum recommended dose during breastfeeding is 25 mg daily to minimize risk of decreased milk supply. 1
• Monitor for adequate infant hydration and weight gain if using HCTZ, particularly at doses exceeding 25 mg/day. 1

Preferred Alternative Regimen

If blood pressure control requires multiple agents, consider switching to first-line agents with established safety profiles:

• Nifedipine XL (RID 2.3-3.4%) - safe first-line calcium channel blocker 1
• Enalapril (RID 1.1%) - safe first-line ACE inhibitor 1
• Labetalol (RID 3.6%) - safe first-line beta-blocker 1

These agents have more extensive safety data and are recommended as first-line options for postpartum hypertension in breastfeeding women. 1

Critical Clinical Considerations

Why Losartan Should Be Avoided

• ARBs as a class lack adequate safety data during lactation. 1
• ACE inhibitors (like enalapril) provide similar therapeutic benefit with established safety profiles and should be used instead. 1
• The theoretical concern with ARBs relates to potential effects on infant renal function, though this has not been studied adequately. 1

Monitoring Parameters

• Assess infant for adequate hydration and weight gain, particularly if mother is taking HCTZ. 1
• Monitor maternal blood pressure control to ensure adequate treatment. 1
• Watch for signs of decreased milk production if using HCTZ doses above 25 mg/day. 1

Common Pitfall to Avoid

Do not unnecessarily discontinue breastfeeding based on outdated or overly cautious pharmaceutical labeling. 4, 5, 6 Most antihypertensive medications have acceptable safety profiles during lactation when evidence-based resources are consulted. 7